Antidepressant activity of fingolimod in mice

Pharmacology Research and Perspectives

Volumn 3, Issue 3, 2015, Pages

  di Nuzzo, Luigi ^a   Orlando, Rosamaria ^b   Tognoli, Cristina ^c   Di Pietro, Paola ^d   Bertini, Giuseppe ^c   Miele, Jessica ^a   Bucci, Domenico ^d   Motolese, Marta ^d   Scaccianoce, Sergio ^a   Caruso, Alessandra ^a   Mauro, Gianluca ^e   De Lucia, Carmine ^a   Battaglia, Giuseppe ^d   Bruno, Valeria ^a,d   Fabene, Paolo Francesco ^c   Nicoletti, Ferdinando ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d IRCCS NEUROMED   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

BDNF; chronic stress; depression; fingolimod; hippocampus

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; FINGOLIMOD; HISTONE H3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; CHRONIC UNPREDICTABLE STRESS; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; HIPPOCAMPUS; HISTONE ACETYLATION; MALE; MORRIS WATER MAZE TEST; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; SOCIAL INTERACTION TEST; SPATIAL LEARNING; SUCROSE PREFERENCE TEST;

EID: 84978406972     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.135     Document Type: Article

References (53)

1. Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, et al. (2013). Metabotropic glutamate 2/3 receptor antagonists improve behavioural and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 65: 29–38.
2. Aktas O, Küry P, Kieseier B, Hartung HP (2010). Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 6: 373–382.
3. Barrientos RM, Sprunger DB, Campeau S, Higgins EA, Watkins LR, Rudy JW, et al. (2003). Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience 121: 847–853.
4. von Bohlen und Halbach O. (2011). Immunohistological markers for proliferative events, gliogenesis, and neurogenesis within the adult hippocampus. Cell Tissue Res 345: 1–19.
5. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 883–897.
6. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al. (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 11: 751–756.
7. Comi G (2013). Disease-modifying treatments for progressive multiple sclerosis. Mult Scler 19: 1428–1436.
8. Compston A, Coles A (2008). Multiple sclerosis. Lancet 372: 1502–1517.
9. Covington HE III, Vialou VF, LaPlant Q, Ohnishi YN, Nestler EJ (2011). Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett 493: 122–126.
10. Cuccurazzu B, Bortolotto V, Valente MM, Ubezio F, Koverech A, Canonico PL, et al. (2013). Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the proneurogenic and antidepressant effects of acetyl-L-carnitine. Neuropsychopharmacology 38: 2220–2230.
11. D'Alisa S, Miscio G, Baudo S, Simone A, Tesio L, Mauro A (2006). Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil 28: 307–314.
12. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, et al. (2009). Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 28: 479–493.
13. Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, Vogt KE, et al. (2012). Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci USA 109: 14230–14235.
14. Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, Jin S, et al. (2013). Fingolimod phosphate attenuates oligomeric amyloid β-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS ONE 8: e61988.
15. Farley S, Dumas S, El Mestikawy S, Giros B (2012). Increased expression of the vesicular glutamate transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. Neuropharmacology 62: 503–517.
16. Feinstein A (2007) Neuropsychiatric syndromes associated with multiple sclerosis. J Neurol 254: II73–II76.
17. Feinstein A (2011). Multiple sclerosis and depression. Mult Scler 17: 1276–1281.
18. Felger JC, Lotrich FE (2013). Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246: 199–229.
19. File SE, Hyde JR (1978). Can social interaction be used to measure anxiety? Br J Pharmacol 62: 19–24.
20. Fukumoto K, Mizoguchi H, Takeuchi H, Horiuchi H, Kawanokuchi J, Jin S, et al. (2014). Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment. Behav Brain Res 268: 88–93.
21. Gourley SL, Taylor JR (2009) Recapitulation and reversal of a persistent depression-like syndrome in rodents. Curr Protoc Neurosci Chapter 9:Unit 9.32.
22. Gräff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, et al. (2012). An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 29: 222–226.
23. Gundersen HJ, Jensen EB (1987). The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229–263.
24. Hait NC, Wise LE, Allegood JC, O'Brien M, Avni D, Reeves TM, et al. (2014). Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci 17: 971–980.
25. Han A, Sung YB, Chung SY, Kwon MS (2014). Possible additional antidepressant-like mechanism of sodium butyrate: targeting the hippocampus. Neuropharmacology 81: 292–302.
26. Hanson ND, Owens MJ, Nemeroff CB (2011). Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 36: 2589–2602.
27. Hoshaw BA, Malberg JE, Lucki I (2005). Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 1037: 204–208.
28. Hsieh J, Eisch AJ (2010). Epigenetics, hippocampal neurogenesis, and neuropsychiatric disorders: unraveling the genome to understand the mind. Neurobiol Dis 39: 73–84.
29. Hunter JW, Hollander E, Miller DM, Cutter G, Agashivala N, Li S, et al. (2013) Impact of Fingolimod on depressive symptoms: post hoc data from the EPOC trial. 29th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis. 2–5 October, Copenhagen, Denmark, P2010.
30. Iijima M, Ito A, Kurosu S, Chaki S (2010). Pharmacological characterization of repeated corticosterone injection-induced depression model in rats. Brain Res 4: 75–80.
31. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R (2005). Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 136: 29–37.
32. King MA, Scotty N, Klein RL, Meyer EM (2002). Particle detection, number estimation, and feature measurement in gene transfer studies: optical fractionator stereology integrated with digital image processing and analysis. Methods 28: 293–299.
33. Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS (2010). Nuclear factor-kappaB is a critical mediator of stress- impaired neurogenesis and depressive behaviour. Proc Natl Acad Sci USA 107: 2669–2674.
34. Krishnan V, Nestler EJ (2010). Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167: 1305–1320.
35. Krishnan V, Nestler EJ (2011). Animal models of depression: molecular perspectives. Curr Top Behav Neurosci 7: 121–147.
36. McNamara RK, Lotrich FE (2012). Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev Neurother 12: 1143–1161.
37. Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732–741.
38. Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, et al. (2014). Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 14: 174–181.
39. Monteggia LM (2007). Elucidating the role of brain-derived neurotrophic factor in the brain. Am J Psychiatry 164: 1790.
40. Nestler EJ, Hyman SE (2010). Animal models of neuropsychiatric disorders. Nat Neurosci 13: 1161–1169.
41. Nibuya M, Morinobu S, Duman RS (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539–7547.
42. di Nuzzo L, Orlando R, Nasca C, Nicoletti F (2014). Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther 8: 555–568.
43. Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F (2005). The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 11: 175–181.
44. Pelletier D, Hafler DA (2012). Fingolimod for multiple sclerosis. N Engl J Med 366: 339–347.
45. Porsolt RD, Brossard G, Hautbois C, Roux S (2001) Rodent models of depression: forced swimming and tail suspension behavioural despair tests in rats and mice. Curr Protoc Neurosci 8:Unit 8.10A.
46. Pothion S, Bizot JC, Trovero F, Belzung C (2004). Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav Brain Res 5: 135–146.
47. Rodgers RJ, Dalvi A (1997). Anxiety, defence and the elevated plus maze. Neurosci Biobehav Rev 21: 801–810.
48. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. (2003). Requirement of hippocampal neurogenesis for the behavioural effects of antidepressants. Science 8: 805–809.
49. Sen S, Duman R, Sanacora G (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64: 527–532.
50. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al. (2003). Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54: 70–75.
51. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioural models of depression. J Neurosci 22: 3251–3261.
52. Sun H, Kennedy PJ, Nestler EJ (2013). Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 38: 124–137.
53. Taliaz D, Stall N, Dar DE, Zangen A (2010). Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviours associated with depression and reduces neurogenesis. Mol Psychiatry 15: 80–92.